Here, we report the first long-term post-HSCT outcomes of two patients with NIK deficiency who underwent HSCT (P1: 10 years; P3: 4 years), providing insight into the clinical trajectory and immunologic reconstitution in the post-transplant setting. This evidence concerns the gene MAP3K14 and hyperinsulinemic hypoglycemia, familial, 4.